乳腺癌肿瘤微环境中间质细胞介导的化疗耐药性研究进展

doi:10.11904/j.issn.1002-3070.2020.04.017

摘要/Abstract

摘要： 乳腺癌是一种具有异质性的全身性疾病,其微环境主要由肿瘤细胞及多种非肿瘤细胞组成。其中间充质干细胞在肿瘤的发生发展中发挥着重要作用。间充质干细胞可直接通过缝隙连接、膜受体和微管或间接通过可溶性分子与肿瘤细胞及其微环境相互作用。肿瘤相关成纤维细胞来源于癌旁成纤维细胞或间充质干细胞,在肿瘤耐药过程中发挥重要作用。在乳腺癌中,肿瘤干细胞与其所处微环境处于动态平衡状态,其表型受细胞因子的密切调控。间质细胞通过与乳腺癌细胞的相互作用,进而对其生物学特性产生重要影响。另外,间质细胞可改变肿瘤细胞对化疗药物的敏感性,进而使其产生耐药。因此,解决肿瘤间质细胞介导的化疗耐药是成功治疗中晚期乳癌的关键。本文主要阐述了间质细胞在乳腺癌微环境中介导化疗耐药的研究进展。

关键词: 乳腺癌, 肿瘤间质细胞, 化疗耐药

Abstract: Breast cancer is a heterogeneous systemic disease.Its microenvironment is mainly composed of tumor cells and a variety of non-tumor cells.Among them,mesenchymal stem cells(MSCs)play an important role in tumorigenesis and development.MSCs can interact with tumor cells and their microenvironment directly through gap junctions,membrane receptors and microtubules,or indirectly through soluble molecules.Tumor-associated fibroblasts(CAFs)are derived from adjacent cancer fibroblasts or MSCs,and play an important role in tumor drug resistance.In breast cancer,tumor stem cells and their microenvironment are in a dynamic equilibrium state,and their phenotype is closely regulated by cytokines.Interstitial cells have an important effect on their biological characteristics through their interaction with breast cancer cells.In addition,interstitial cells can change the sensitivity of tumor cells to chemotherapeutic drugs,which in turn make them resistant.Therefore,addressing tumor stromal cell-mediated resistance to chemotherapy is the key to successful treatment of advanced breast cancer.This article mainly describes the research progress of stromal cells in the microenvironment mediated chemotherapy resistance of breast cancer.

Key words: Breast cancer, Tumor mesenchymal cells, Chemotherpy resistance

中图分类号:

R737.9

陈都, 钱诚. 乳腺癌肿瘤微环境中间质细胞介导的化疗耐药性研究进展[J]. 实用肿瘤学杂志, 2020, 34(4): 382-386.

CHEN Du, QIAN Cheng. Research progress of mesenchymal cell-mediated chemotherapy resistance in tumor microenvironment of breast cancer[J]. Journal of Practical Oncology, 2020, 34(4): 382-386.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2020.04.017

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2020/V34/I4/382

参考文献

1 Kadakia KC,Kidwell KM,Barton DL,et al.Factors influencing the use of extended adjuvant endocrine therapy[J].Breast Cancer Res Treat,2019,175(1):181-189.
2 Guo F,Kuo YF,Shih Y,et al.Trends in breast cancer mortality by stage at diagnosis among young women in the United States[J].Cancer,2018,124(17):3500-3509.
3 Plava J,Cihova M,Burikova M,et al.Recent advances in understanding tumor stroma-mediated chemoresistance in breast cancer[J].Mol Cancer,2019,18(1):67.
4 Halama N,Zoernig I,Berthel A,et al.Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients[J].Cancer Cell,2016,29(4):587-601.
5 Autenshlyus AI,Davletova KI,Studenikina AA,et al.Cytokine production by blood immune cells,tumor and its microenvironment,characteristic of extracellular matrix in patients with invasive ductal carcinoma of no special type[J].Biomed Khim,2019,65(5):424-431.
6 Kucerova L,Durinikova E,Toro L,et al.Targeted antitumor therapy mediated by prodrug-activating mesenchymal stromal cells[J].Cancer Lett,2017,408:1-9.
7 Sridharan S,Howard CM,Tilley A,et al.Novel and alternative targets against breast cancer stemness to combat chemoresistance[J].Front Oncol,2019,9:1003.
8 Grisendi G,Spano C,Rossignoli F,et al.Tumor stroma manipulation by MSC[J].Curr Drug Targets,2016,17(10):1111-1126.
9 Ireland LV,Mielgo A.Macrophages and fibroblasts,key players in cancer chemoresistance[J].Front Cell Dev Biol,2018,6:131.
10 Borriello L,Nakata R,Sheard MA,et al.Cancer-associated fibroblasts share characteristics and protumorigenic activity with mesenchymal stromal cells[J].Cancer Res,2017,77(18):5142-5157.
11 Su S,Chen J,Yao H,et al.CD10+GPR77+ cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness[J].Cell,2018,172(4):841-856.
12 Melzer C,Yang Y,Hass R.Interaction of MSC with tumor cells[J].Cell Commun Signal,2016,14(1):20.
13 Zhou X,Li T,Chen Y,et al.Mesenchymal stem cell derived extracellular vesicles promote the in vitro proliferation and migration of breast cancer cells through the activation of the ERK pathway[J].Int J Oncol,2019,54(5):1843-1852.
14 Kucerova L,Durinikova E,Toro L,et al.Targeted antitumor therapy mediated by prodrug-activating mesenchymal stromal cells[J].Cancer Lett,2017,408:1-9.
15 Hill BS,Pelagalli A,Passaro N,et al.Tumor-educated mesenchymal stem cells promote pro-metastatic phenotype[J].Oncotarget,2017,8(42):73296-73311.
16 Rhee KJ,Lee JI,Eom YW.Mesenchymal stem cell-mediated effects of tumor support or suppression[J].Int J Mol Sci,2015,16(12):30015-30033.
17 Han HR,Park SA,Ahn S,et al.Evaluation of combination treatment effect with trail-secreting mesenchymal stem cells and compound c against glioblastoma[J].Anticancer Res,2019,39(12):6635-6643.
18 Maffey A,Storini C,Diceglie C,et al.Mesenchymal stem cells from tumor microenvironment favour breast cancer stem cell proliferation,cancerogenic and metastatic potential,via ionotropic purinergic signalling[J].Sci Rep,2017,7(1):13162.
19 Jin OH,Hee WL,Kyoung WS,et al.Anti-tumor effect of adipose tissue derived-mesenchymal stem cells expressing interferon-β and treatment with cisplatin in a xenograft mouse model for canine melanoma[J].PLoS One,2013,8(9):e74897.
20 Chan TS,Shaked Y,Tsai KK.Targeting the interplay between cancer fibroblasts,mesenchymal stem cells,and cancer stem cells in desmoplastic cancers[J].Front Oncol,2019,9:688.
21 Smit L,Berns K,Spence K,et al.An integrated genomic approach identifies that the PI3K/Akt/FOXO pathway is involved in breast cancer tumor initiation[J].Oncotarget,2016,7(3):2596-2610.
22 Woosley AN,Dalton AC,Hussey GS,et al.TGFβ promotes breast cancer stem cell self-renewal through an ILEI/LIFR signaling axis[J].Oncogene,2019,38(20):3794-3811.
23 Miller-KJ,Guo X,Qian W,et al.Dual-targeting wnt and upa receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer[J].Biomaterials,2018,152:47-62.
24 Costa A,Kieffer Y,Scholer DA,et al.Fibroblast heterogeneity and immunosuppressive environment in human breast cancer[J].Cancer Cell,2018,33(3):463-479.
25 Morgan MM,Livingston MK,Warrick JW,et al.Mammary fibroblasts reduce apoptosis and speed estrogen-induced hyperplasia in an organotypic MCF7-derived duct model[J].Sci Rep,2018,8(1):7139.
26 Wilson TR,Fridlyand J,Yan Y,et al.Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors[J].Elife,2014,3(7408):505-509.
27 Kalluri R.The biology and function of fibroblasts in cancer[J].Nat Rev Cancer,2016,16(9):582-598.
28 Unger C,Kramer N,Unterleuthner D,et al.Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms[J].Oncogene,2017,36(38):5341-5355.
29 Chan TS,Hsu CC,Pai VC,et al.Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells[J].J Exp Med,2016,213(13):2967-2988.
30 Wilcken N,Zdenkowski N,White M,et al.Systemic treatment of HER2-positive metastatic breast cancer:A systematic review[J].Asia Pac J Clin Oncol,2014,10:1-14.
31 Zhong H,Davis A,Ouzounova M,et al.A novel il6 antibody sensitizes multiple tumor types to chemotherapy including trastuzumab-resistant tumors[J].Cancer Res,2016,76(2):480-490.
32 Liu S,Ginestier C,Ou SJ,et al.Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks[J].Cancer Res,2011,71(2):614-624.
33 Ono M,Kosaka N,Tominaga N,et al.Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells[J].Sci Signal,2014,7(332):63.
34 Cai Y,Xi Y,Cao Z,et al.Dual targeting and enhanced cytotoxicity to HER2-overexpressing tumors by immunoapoptotin-armored mesenchymal stem cells[J].Cancer Lett,2016,381(1):104-112.
35 Jiménez G,Hackenberg M,Catalina P,et al.Mesenchymal stem cell's secretome promotes selective enrichment of cancer stem-like cells with specific cytogenetic profile[J].Cancer Lett,2018,429:78-88.
36 Rudnick JA,Arendt LM,Klebba I,et al.Functional heterogeneity of breast fibroblasts is defined by a prostaglandin secretory phenotype that promotes expansion of cancer-stem like cells[J].PLoS One,2011,6(9):e24605.
37 Lim B,Woodward WA,Wang X,et al.Inflammatory breast cancer biology:the tumour microenvironment is key[J].Nat Rev Cancer,2018,18(8):485-499.
38 Valenti G,Quinn HM,Heynen G,et al.Cancer stem cells regulate cancer-associated fibroblasts via activation of hedgehog signaling in mammary gland tumors[J].Cancer Res,2017,77(8):2134-2147.
39 Ireland L,Santos A,Campbell F,et al.Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer[J].Oncogene,2018,37(15):2022-2036.
40 Schott AF,Goldstein LJ,Cristofanilli M,et al.Phase ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with her-2-negative metastatic breast cancer[J].Clin Cancer Res,2017,23(18):5358-5365.
41 Steele CW,Karim SA,Leach J,et al.CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma[J].Cancer Cell,2016,29(6):832-845.

[1]	赵仁成, 林子棠, 余卫军, 雷林, 刘峥, 徐英, 郭艳芳, 彭绩. 2017—2019年深圳市宝安区40~74岁常住居民五癌风险流行状况分析[J]. 实用肿瘤学杂志, 2020, 34(4): 315-320.
[2]	仝潇, 邢佳妮, 王丽虹. 长链非编码RNA HCP5通过调控凋亡通路促进三阴性乳腺癌的研究[J]. 实用肿瘤学杂志, 2020, 34(4): 321-327.
[3]	刘思奇, 边娜娜, 苏亚娟. 超声BI-RADS联合血CA15-3和CEA在乳腺肿物诊断中的价值研究[J]. 实用肿瘤学杂志, 2020, 34(4): 347-351.
[4]	张锐, 李志高. 粘液性乳腺癌的临床研究进展[J]. 实用肿瘤学杂志, 2020, 34(4): 377-381.
[5]	谢贤鑫, 韦军, 邱佳鑫, 王聪, 姜大庆. 乳腺癌新辅助化疗残余肿瘤组织病理信息与预后分析[J]. 实用肿瘤学杂志, 2020, 34(3): 225-231.
[6]	李慧, 庞达. 三阳型乳腺癌的临床病理学特点及辅助治疗[J]. 实用肿瘤学杂志, 2020, 34(3): 262-265.
[7]	赵云霞, 牛波. LncRNA NBAT1通过调控miR-3664-5p/Caspase 9分子轴对人乳腺癌细胞增殖的影响[J]. 实用肿瘤学杂志, 2020, 34(1): 24-29.
[8]	李国政, 庞达. HER2阳性乳腺癌治疗的研究进展[J]. 实用肿瘤学杂志, 2020, 34(1): 74-78.
[9]	曹涤非, 黄国庆, 薛佳莹, 吴琼, 王雷, 李瑶. CA153在乳腺癌免疫治疗中的作用[J]. 实用肿瘤学杂志, 2019, 33(6): 566-569.
[10]	沈依哲, 郭宝良. 初诊Ⅳ期乳腺癌的局部治疗研究进展[J]. 实用肿瘤学杂志, 2019, 33(6): 575-578.
[11]	师镘茹, 鄂明艳. 放疗延迟对乳腺癌不同分子亚型患者预后的影响[J]. 实用肿瘤学杂志, 2019, 33(5): 431-435.
[12]	李磊 , 张清媛. 乳腺癌抗肿瘤血管治疗的临床进展[J]. 实用肿瘤学杂志, 2019, 33(5): 461-465.
[13]	王宇, 乔娟娟, 张磊, 刘四卫 , 杨树才. 类固醇激素在乳腺癌中的作用及对肿瘤干细胞的影响[J]. 实用肿瘤学杂志, 2019, 33(5): 466-470.
[14]	刘尔钰, 杨昊, 梁国华, 赵晏方, 赵文辉. CDK4/6抑制剂联合mTOR抑制剂在乳腺癌中的作用机制[J]. 实用肿瘤学杂志, 2019, 33(5): 476-480.
[15]	安巍巍, 唐雅莉, 赵莲花, 杨悦, 王新玲. 红松松塔提取物多聚苯丙素-多糖复合物诱导人乳腺癌MCF-7细胞凋亡[J]. 实用肿瘤学杂志, 2019, 33(4): 289-293.